Logo for STRIVE obesity services study
Title: Effectiveness and cost of integrating a protocol with use of Liraglutide 3.0mg into an obesity service
Principal Investigator – Dr David Webb
Study start date: November 2017
Adults with obesity are at increased risk of developing associated health complications compared to patients who are of normal weight. Liraglutide 3.0mg (Saxenda) is a drug recently approved for the treatment of obesity and has been shown to improve blood pressure and diabetes control, as well as prevent diabetes development in those with pre-diabetes.
However, Liraglutide 3.0mg (Saxenda) is not equally effective in all people with obesity and the high cost of the medication makes it less attractive to the health service for use routinely in obesity clinics. Previous studies have shown that patients who achieve significant weight loss in the first months of treatment will be able to achieve more than 15 per cent weight loss at one year after the treatment (early/good responders).
The aim of this study is to investigate the effectiveness and cost-effectiveness of Liraglutide 3.0mg (Saxenda) in the weight management service with a protocol for targeted use of the medication in patients who are “early” and “good” responders to the treatment. This approach is expected to minimise the side-effects and unnecessary exposure of those who will not achieve significant weight loss with the drug, optimise the costs of the medications and target the patients who will benefit more from its use.
For more information, contact the STRIVE study team on 0116 258 4499 / 0116 258 8596.